Literature DB >> 19707688

In silico study of MMP inhibition.

Matthieu Rouffet1, Clément Denhez, Erika Bourguet, Frédéric Bohr, Dominique Guillaume.   

Abstract

Lack of enzyme inhibition selectivity is frequently the major drawback preventing the development of enzyme inhibitors. Sulfonylhydrazides have recently been suggested to act as zinc ligands. Consequently, such derivatives potentially possess important industrial or therapeutic implications. DFT calculations (B3LYP/6-31G**+LANL2DZ theory level) of the binding modes and free energies of binding of a variety of N-acetyl-N'-sulfonylhydrazides in the presence of a Zn(2+) ion embedded in an MMP active site model show that protonated and deprotonated sulfonylhydrazides bind the Zn(2+) ion according to different modes. These results strongly suggest that sulfonylhydrazides can be developed as selective metalloprotease inhibitors, and the results of molecular docking computations fully support this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19707688     DOI: 10.1039/b910543c

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  3 in total

1.  Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12.

Authors:  Amanda Cobos-Correa; Frank Stein; Carsten Schultz
Journal:  ACS Med Chem Lett       Date:  2012-07-14       Impact factor: 4.345

2.  Molecular modeling of non-covalent binding of Ligustrum lucidum secoiridoid glucosides to AP-1/matrix metalloproteinase pathway components.

Authors:  Pathomwat Wongrattanakamon; Piyarat Nimmanpipug; Busaban Sirithunyalug; Wantida Chaiyana; Supat Jiranusornkul
Journal:  J Bioenerg Biomembr       Date:  2018-04-23       Impact factor: 2.945

3.  Explaining the interaction of mangiferin with MMP-9 and NF-ƙβ: a computational study.

Authors:  Andy Gálvez-Rodríguez; Anthuan Ferino-Pérez; Zalua Rodríguez-Riera; Idania Rodeiro Guerra; David Řeha; Babak Minofar; Ulises J Jáuregui-Haza
Journal:  J Mol Model       Date:  2022-08-20       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.